Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“It is a very exciting time in Cancer Immunotherapy!
One Question… Which cancer antigens are important??
That is one question that will be discussed in the session ‘Navigating Existing Challenges in Cancer Vaccine Research and Development’?
Your choices?
- neoantigens
- TAA Tumor Associated Antigens Aberantly Expressed antigens or
- Dark Genome-derived Dark Matter antigens, also known as non-canonical or cryptic antigens
Do they need to be restricted to cancer?
I had a wonderful time with Prof. Ron Levy of Stanford University – He is an icon in the field, and to quote him… He is in favor of ‘whatever works’.
Cancer antigens are some of what the American Association for Cancer Research and CancerVaccineCoalition Think Tank will focus on over the next two days. But there will be more.
This event is hosted by HSBC Innovation Banking, and it is encouraging to see support from various organizations, including the National Basketball Association (NBA), Pfizer, Northwest Biotherapeutics, Anixa Biosciences, EchoImmune, ILENE BEAL CHARITABLE FDN, WACKER | Biotech, and BeatCancerDaily.
Will note I am wearing one of Prof. Jeffrey S. Weber’s Paul Stuart bow ties. RIP Jeff.”
More posts featuring Bernard A. Fox.
